- This event has passed.
Exploring the Potential for Risk Reduction and Right Heart Reverse Remodeling in PAH: A Focus on Upfront Combination Therapy
October 20, 2021 from 5:00 pm - 6:00 pm CDT
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson
Pulmonary arterial hypertension (PAH) is a rapidly progressive disease that is fatal when left untreated. It is characterized by pulmonary vasoconstriction and vascular remodeling, which in turn leads to increased pulmonary vascular resistance and arterial pressure, decreased cardiac output, and ultimately right heart failure. In recent years, standard of care treatment has moved away from sequential monotherapy to upfront combination therapy. To ensure that clinicians are well-equipped to provide optimal PAH management, this educational program will provide up-to-date information on clinical trial evidence regarding the efficacy and safety of combination (dual and triple) treatment strategies. Additionally, the program will also address the role of noninvasive testing (eg, echocardiography) in early diagnosis, assessment of treatment response, and disease monitoring, as well as the importance of multidisciplinary care throughout the course of care.
Disclaimer: This symposium is not supported, endorsed, or accredited by the American College of Chest Physicians
John Ryan MD, MB, BCh, BAO, MRCPI, FACC, FAHA
University of Utah School of Medicine
Faculty Director of Cardiology Education
Salt Lake City, UT
Vallerie V McLaughlin MD
University of Michigan
Professor of Internal Medicine
Ann Arbor, MI
Registration: Register Here